Cholestatic Pruritus Market Report 2026

Cholestatic Pruritus Market Overview

• Cholestatic Pruritus market size has reached to $20.22 billion in 2025 • Expected to grow to $25.99 billion in 2030 at a compound annual growth rate (CAGR) of 5.1% • Growth Driver: Increasing Prevalence Of Liver Diseases Driving Growth In The Market • Market Trend: Improving Patient Compliance With Once-Daily Oral Treatments • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Cholestatic Pruritus Market?

Cholestatic pruritus refers to severe itching caused by the buildup of bile acids in the skin, typically resulting from liver diseases that impair bile flow. This condition can significantly affect a patient's quality of life and often requires targeted treatment to manage the discomfort and address the underlying liver dysfunction. The main disease types of cholestatic pruritus are primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC), intrahepatic cholestasis of pregnancy (ICP), and other disease types. Primary biliary cholangitis (PBC) is a chronic autoimmune liver disease that causes progressive destruction of the bile ducts, leading to bile buildup, liver damage, and potential cirrhosis. Treatment options for cholestatic pruritus include medications, phototherapy, and other treatment types, with routes of administration such as oral, topical, and injectable. The key end-users for these treatments are hospitals, clinics, ambulatory care centers, and home care.

What Is The Cholestatic Pruritus Market Growth Forecast?

The cholestatic pruritus market size is expected to see strong growth in the next few years. It will grow to $25.99 billion in 2030 at a compound annual growth rate (CAGR) of 5.1%. The growth in the forecast period can be attributed to increasing approval of novel therapeutics, rising focus on quality-of-life improvement, expansion of targeted liver disease drugs, growing investment in rare disease research, increasing adoption of personalized treatment plans. Major trends in the forecast period include increasing development of targeted anti-pruritic therapies, rising focus on symptom-specific treatment approaches, growing use of oral bile acid modulators, expansion of research in liver disease management, enhanced patient-centered care strategies.

What Is The Driver Of The Cholestatic Pruritus Market?

The increasing prevalence of liver diseases is expected to propel the growth of the cholestatic pruritus market going forward. Liver diseases are a broad range of conditions that affect liver function, including infections, autoimmune disorders, genetic diseases, and damage from toxins, leading to inflammation, scarring, or liver failure. The growing prevalence of liver diseases is fueled by increasing obesity, diabetes, alcohol use, viral hepatitis infections, and exposure to toxins and environmental factors. Cholestatic pruritus helps in the identification and management of liver diseases by serving as a key symptom that indicates impaired bile flow, often prompting further investigation and treatment of underlying hepatic conditions. For instance, in 2023, According to the Office for Health Improvement and Disparities (OHID), UK-Based government agency, In England, there were 85,665 hospital admissions for liver disease during the financial year ending in 2023. Therefore, the increasing prevalence of liver diseases will drive the growth of the cholestatic pruritus industry.

Key Players In The Global Cholestatic Pruritus Market

Major companies operating in the cholestatic pruritus market are GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Merck KGaA, Incyte Corporation, Ipsen Pharma, CANbridge Pharmaceuticals Inc., Escient Pharmaceuticals Inc., Mirum Pharmaceuticals Inc., Albireo Pharma Inc., Cara Therapeutics Inc., CymaBay Therapeutics Inc., Gilead Sciences Inc., Zydus Lifesciences, Genfit SA, NGM Biopharmaceuticals Inc., Calliditas Therapeutics AB, Avior Inc, Travere Therapeutics Inc., 89bio, Hepion Pharmaceuticals, Liminal BioSciences, ProQR Therapeutics NV.

Global Cholestatic Pruritus Market Trends and Insights

Major companies operating in the cholestatic pruritus market are focusing on developing innovative solutions, such as oral solutions to manage symptoms more effectively, improve patient compliance, and provide targeted relief by addressing the underlying causes of bile salt accumulation and inflammation. An oral solution for the treatment of cholestatic pruritus is a liquid formulation of medication designed to reduce bile acid accumulation and alleviate severe itching in patients with cholestasis. For instance, in March 2024, Mirum Pharmaceuticals Inc., a US-based biopharmaceutical company, received approval from the U.S. Food and Drug Administration (FDA) for LIVMARLI (maralixibat) oral solution for treating cholestatic pruritus in patients aged five and older with progressive familial intrahepatic cholestasis (PFIC). This once-daily, orally administered ileal bile acid transporter inhibitor holds a breakthrough therapy designation for PFIC type 2. LIVMARLI is poised to make a significant impact on patients with cholestatic pruritus linked to PFIC, offering a much-needed treatment option for those with the rarest subtypes.

What Are Latest Mergers And Acquisitions In The Cholestatic Pruritus Market?

In September 2023, Travere Therapeutics Inc., a US-based biopharmaceutical company, partnered with Mirum Pharmaceuticals Inc. With this partnership, Travere aims to focus on its core therapeutic areas while enabling Mirum Pharmaceuticals to expand its portfolio and continue the development and commercialization of bile acid therapies for rare liver diseases. Mirum Pharmaceuticals Inc. is a US-based company focused on developing and commercializing therapies for rare liver diseases, including those that lead to cholestatic pruritus.

What Defines the Cholestatic Pruritus Market?

The cholestatic pruritus market consists of revenues earned by entities by providing services such as diagnosis and screening services, medical consultations and treatment management, patient support programs, and counseling. The market value includes the value of related goods sold by the service provider or included within the service offering. The cholestatic pruritus market also includes sales of ursodeoxycholic acid, topical corticosteroids, and opioid antagonists. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Cholestatic Pruritus Market Report 2026?

The cholestatic pruritus market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the cholestatic pruritus industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.